A Study of BI 853520 in Japanese and Taiwanese Patients With Various Types of Advanced or Metastatic Cancer

Inclusion criteria: * Patients with a confirmed diagnosis of advanced, measurable or evaluable, non-resectable and/or metastatic non-hematologic malignancy, which has shown to be progressive in the last 6 months * Patients who have failed conventional treatment or for whom no therapy of proven efficacy exists or who are not amenable to established treatment options * Recovery from reversible toxicities (alopecia excluded) of prior anti-cancer therapies (Common Terminology Criteria for Adverse Events grade \<2) * Age \>= 20 years * Written informed consent in accordance with International Conference on Harmonisation/Good Clinical Practice (ICH/GCP) and local legislation * Eastern Cooperative Oncology Group (ECOG), performance score 0-1 Exclusion criteria: * Serious concomitant non-oncological disease/illness * Active/symptomatic brain metastases * Second malignancy * Pregnancy or breastfeeding * Women or men who are sexually active and unwilling to use a medically acceptable method of contraception. * Treatment with cytotoxic anti-cancer-therapies or investigational drugs within four weeks of the first treatment with the study medication